Preclinical pharmacology, antitumor activity and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930

MLA

John Caldwell, et al. Preclinical Pharmacology, Antitumor Activity and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930. Dec. 2010. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2391b9e33067d4b15de78f9959a67d68&authtype=sso&custid=ns315887.

APA

John Caldwell, Neil T. Thompson, Florence I. Raynaud, Alexis De Haven Brandon, Paul D. Eve, Ruth Ruddle, Ian Collins, L.K. Hunter, Gowri Vijayaraghavan, Wynne Aherne, Simon P. Heaton, Michael I. Walton, Paul Workman, Alan T. Henley, Lisa Pickard, Suzanne A. Eccles, Timothy A. Yap, Melanie Valenti, & Michelle D. Garrett. (2010). Preclinical pharmacology, antitumor activity and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.

Chicago

John Caldwell, Neil T. Thompson, Florence I. Raynaud, Alexis De Haven Brandon, Paul D. Eve, Ruth Ruddle, Ian Collins, et al. 2010. “Preclinical Pharmacology, Antitumor Activity and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930,” December. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2391b9e33067d4b15de78f9959a67d68&authtype=sso&custid=ns315887.